Bortiv 1 Mg/0.4 Ml, 2.5 Mg/Ml & 3.5 Mg/1.4 Ml 1 mg/0.4 ml, 2.5 mg/ml & 3.5 mg/1.4 ml Solution for Injection
PDF Leaflet Revision Date: 22 July 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of multiple myeloma and mantle cell lymphoma.
Dosage (summary)
1.3 mg/mu00b2 twice weekly for two weeks, followed by a rest period.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; safety in lactation not established.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- Concomitant medications causing peripheral neuropathy
Contraindications
- Hypersensitivity
- Acute diffuse infiltrative pulmonary disease
Common side effects
- Nausea
- Diarrhea
- Constipation
- Fatigue
- Thrombocytopenia
- Peripheral neuropathy
Counselling Points
- Monitor for signs of neuropathy
- Avoid pregnancy during treatment
- Hydration for gastrointestinal toxicity
Serious warnings
- Fatal intrathecal administration
- Cardiac failure
- Pulmonary disorders
Important Disclaimer
The Bortiv 1 Mg/0.4 Ml, 2.5 Mg/Ml & 3.5 Mg/1.4 Ml 1 mg/0.4 ml, 2.5 mg/ml & 3.5 mg/1.4 ml Solution for Injection professional information leaflet below is the property of Hetero Drugs South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
